Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway
Advanced Science · 2025-03 · 12 (11)
DOI: 10.1002/advs.202409419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.01.2025. Verfasst von Jiayu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. Hauptthemen laut MEDLINE: Crohn Disease, Myeloid Differentiation Factor 88, Osteonectin, Intestinal Mucosa. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Laboratory of Jiangsu Province for Chemical Pollution Control and Resources Reuse, National Natural Science Foundation of China.
Abstract (Originalsprache)
Disruption of the intestinal epithelial barrier results in increased permeability and is a key factor in the onset and progression of Crohn's disease (CD). The protein SPARC is primarily involved in cell interaction and migration, but its specific role in the intestinal epithelial barrier remains unclear. This study demonstrates that SPARC is significantly overexpressed in both CD patients and murine models of colitis. Furthermore, mice deficient in SPARC exhibits resistance to chemically induced colitis, a phenomenon associated with the modulation of barrier‐associated proteins. Mechanistically, it is elucidated that SPARC competitively binds to OTUD4 in conjunction with MYD88, facilitating the translocation of p65 from the cytoplasm to the nucleus and subsequent activation of the p65‐MLCK/MLC2 pathway, thereby compromising barrier integrity. Additionally, it is identified that the elevated expression of SPARC in CD is regulated via the METTL3‐YTHDF1 axis. These findings indicate that SPARC levels are elevated in patients with CD and in colitis‐induced mice, leading to intestinal barrier damage through direct interaction with OTUD4 and subsequent activation of the MYD88/p65/MLCK/MLC2 signaling pathway. Consequently, targeting SPARC or the OTUD4/MYD88/p65/MLCK/MLC2 axis may offer novel insights into the molecular mechanisms underlying CD and represent a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
- Jiangsu Key Laboratory of Clinical Immunology, Soochow University, Suzhou, 215000, China.
- Infectious Disease Department, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, 215000, China.
ORCID-Profile: Tongguo Shi, Weichang Chen
Förderung
- Key Laboratory of Jiangsu Province for Chemical Pollution Control and Resources Reuse
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., He, Y., Zhu, X., Zhu, J., Deng, Z., Zhang, H., Chen, Y., Zhang, G., Shi, T., & Chen, W. (2025). Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway. Advanced Science, 12(11). https://doi.org/10.1002/advs.202409419
Vancouver
Wang J, He Y, Zhu X, Zhu J, Deng Z, Zhang H, et al. Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway. Advanced Science. 2025;12(11). doi:10.1002/advs.202409419
BibTeX
@article{Wang2025,
author = {Wang, Jiayu and He, Yuxin and Zhu, Xingchao and Zhu, Jinghan and Deng, Zilin and Zhang, Huan and Chen, Yanjun and Zhang, Guangbo and Shi, Tongguo and Chen, Weichang},
title = {Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn's Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {11},
doi = {10.1002/advs.202409419}
}
EUVIMED